THE SAFETY AND TOLERABILITY OF REGADENOSON IN PATIENTS WITH END-STAGE RENAL DISEASE: THE FIRST PROSPECTIVE EVALUATION
| Autor: | Maria Octavia Rangel, Rojina Pant, Rami Doukky, Raysa Morales-Demori, Rizcallah Dick, Marwan Wassouf, Bosko Margeta |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
medicine.medical_specialty
business.industry hemic and immune systems chemical and pharmacologic phenomena Retrospective cohort study Disease urologic and male genital diseases medicine.disease female genital diseases and pregnancy complications humanities Regadenoson End stage renal disease Clinical trial Tolerability Internal medicine medicine Stage (cooking) Cardiology and Cardiovascular Medicine business Kidney disease medicine.drug |
| Zdroj: | Journal of the American College of Cardiology. 59:E1313 |
| ISSN: | 0735-1097 |
| Popis: | Regadenoson (REG) appears to be safe in patients with end-stage renal disease (ESRD) on the basis of two retrospective studies. A prospective, placebo-controlled clinical trial by Palani et al found REG to be safe in chronic kidney disease (CKD) stage III-IV. However, there has not been a |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|